Two new faculty members have joined the UNC Lineberger Comprehensive Cancer Center to help launch groundbreaking immunotherapy clinical trials that will test an experimental treatment in which patients’ own immune cells are genetically engineered to fight their cancer.
Chuck Perou, PhD, professor of Genetics and Pathology at UNC Lineberger Comprehensive Cancer Center, was recently interviewed by Oncology Times for the publication's "Three Questions" series.
While studies have shown that the colonoscopy can reduce the risk of death from colorectal cancer, researchers have also shown that not all people recommended for the test actually get it.
A study led by a UNC Lineberger Comprehensive Cancer Center researcher has found that, despite a North Carolina law banning their purchase by minors and requiring online vendors to verify customer age, teens can easily buy electronic cigarettes online.
Hepatitis C virus infection is a common cause of liver disease and of liver cancer in the United States. Through a new study that explores one aspect of how the virus hijacks host cell machinery to replicate itself, UNC Lineberger Comprehensive Cancer Center researchers have gained insight into the workings of a potential drug target for hepatitis C.
The latest installment in our Real Medicine video series features one of our Patient Ambassadors for North Carolina Children's Hospital.
Scientists from UNC-Chapel Hill have created a new way to investigate epigenetic mechanisms important in diseases ranging from Alzheimer’s to cancers.
Device that drives drugs into solid tumors that are poorly vascularized opens the possibility of life-saving surgeries in cancer patients. James Byrne, PhD, a medical student and member of Joseph DeSimone’s lab, led the research by constructing the device and examining its ability to deliver chemotherapeutic drugs effectively to pancreatic cancer tumors, as well as two types of breast cancer tumors.
A study co-led by a UNC Lineberger Comprehensive Cancer Center researcher has identified genomic changes in head and neck cancers linked to the sexually transmitted disease HPV -- the latest finding of a collaborative scientific effort designed to map out the genomic changes driving cancer.
UNC geneticists led by Terry Magnuson, PhD, and Ron Chandler, PhD, create the first mouse model of ovarian clear cell carcinoma; show how a known drug can suppress tumor growth.
The Duke Endowment awards $461,750 grant to UNC Lineberger’s Comprehensive Cancer Support Program.
Graduate student Kathleen Mulvaney investigates the newly discovered interplay between two of the proteins that allow cells to divide.
Researchers in the joint UNC-NCSU biomedical engineering department have used nanoscale graphene to improve upon traditional delivery of two cancer drugs.
Carolina legend Danny Talbott performed at the highest level on both the football field and baseball diamond during his years as a Tar Heel. Since 2010, he’s been back in Chapel Hill, battling the toughest opponent he’s faced: multiple myeloma. He can’t imagine going anywhere else to do it.
The common chemotherapy drug topotecan disrupts a gene integral for neuron communication, though the effects are reversible. The research also homes in on an underlying cause of autism.
Edward Miao, MD, PhD, earns a Jefferson-Pilot Award for his groundbreaking work on the interplay between dangerous pathogens and the human immune response.
Our own immune cells can destroy other healthy cells to cause severe and chronic diseases. Maureen Su, MD, a 2014 Jefferson-Pilot award winner, studies how this autoimmunity happens and what it might tell us about potential cancer therapies.
A novel siRNA-based molecule, developed by Chad Pecot, MD, successfully targets KRAS, a well-studied but hard to halt protein important for cancer development and metastasis.
UNC Lineberger Comprehensive Cancer Center and the UNC Institute for Global Health & Infectious Diseases have received a $3.7 million grant from the National Cancer Institute (NCI) to study the growing worldwide cancer problem and expand the University’s efforts in Malawi to study and treat HIV-associated cancers.
The research, led by Andrew C. Dudley, PhD, has implications for developing cancer drugs that target blood vessels that feed tumors.